Turning Point Therapeutics to Participate in Guggenheim Oncology Day

    NEXT STORY
    Translational Research in Oncology (TRIO) Appoints Industry and Clinical Experts to Board of Directors
    PREV STORY
    CorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin® New Drug Application
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19

    author_avatar
    NASDAQ Market News

    FibroGen Reports First Quarter 2018 Financial Results

    Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase ...

    author_avatar
    NASDAQ Market News

    Idera Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Provides Corporate Update

    CAMBRIDGE, Mass. and EXTON, Pa., March 10, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ...

    author_avatar
    NASDAQ Market News